First Eagle Investment Management LLC Boosts Holdings in CareDx, Inc. $CDNA

First Eagle Investment Management LLC raised its holdings in CareDx, Inc. (NASDAQ:CDNA) by 15.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 379,023 shares of the company’s stock after purchasing an additional 50,409 shares during the period. First Eagle Investment Management LLC’s holdings in CareDx were worth $7,406,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of CDNA. MCF Advisors LLC raised its position in shares of CareDx by 292.9% during the 2nd quarter. MCF Advisors LLC now owns 1,336 shares of the company’s stock worth $26,000 after purchasing an additional 996 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in CareDx by 20,200.0% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,466 shares of the company’s stock valued at $79,000 after buying an additional 4,444 shares during the last quarter. Morse Asset Management Inc purchased a new position in CareDx during the first quarter worth $103,000. AlphaQuest LLC raised its holdings in shares of CareDx by 40.0% in the second quarter. AlphaQuest LLC now owns 9,576 shares of the company’s stock worth $187,000 after acquiring an additional 2,736 shares during the last quarter. Finally, Moors & Cabot Inc. purchased a new stake in shares of CareDx in the first quarter valued at $201,000.

CareDx Stock Up 4.1%

Shares of NASDAQ CDNA opened at $15.62 on Friday. The stock has a market capitalization of $831.41 million, a PE ratio of 15.31 and a beta of 2.50. The firm has a fifty day moving average of $14.53 and a 200-day moving average of $15.60. CareDx, Inc. has a 52-week low of $10.96 and a 52-week high of $26.37.

CareDx (NASDAQ:CDNA) last issued its earnings results on Tuesday, November 4th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.10). CareDx had a net margin of 17.97% and a return on equity of 18.03%. The firm had revenue of $100.06 million during the quarter, compared to analyst estimates of $95.25 million. During the same quarter in the previous year, the business posted ($0.14) EPS. CareDx’s revenue was up 20.7% compared to the same quarter last year. CareDx has set its FY 2025 guidance at EPS. Equities research analysts expect that CareDx, Inc. will post -0.9 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. BTIG Research lifted their price objective on CareDx from $22.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CareDx in a research note on Wednesday, October 8th. William Blair began coverage on shares of CareDx in a research report on Tuesday, August 26th. They issued a “market perform” rating for the company. Zacks Research lowered shares of CareDx from a “hold” rating to a “strong sell” rating in a research report on Monday, October 20th. Finally, Craig Hallum lowered their target price on shares of CareDx from $40.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, July 18th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, CareDx currently has an average rating of “Hold” and a consensus price target of $26.00.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.